Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome

American Journal of Gastroenterology

Volumn 110, Issue 9, 2015, Pages 1339-1346

  Ringel Kulka, Tamar ^a   Choi, Chang Hwan ^b,c   Temas, Daniel ^b   Kim, Ari ^a,d   Maier, Daniele M ^b   Scott, Karen ^e   Galanko, Joseph A ^b   Ringel, Yehuda ^f  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Chung Ang University College of Medicine   (South Korea)

^d Wonkwang University School of Medicine   (South Korea)

^e ROWETT RESEARCH INSTITUTE   (United Kingdom)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

VOLATILE FATTY ACID;

ADOLESCENT; ADULT; BACTERIUM; CHEMISTRY; COLON; FECES; FEMALE; FERMENTATION; FOLLOW UP; HUMAN; IRRITABLE BOWEL SYNDROME; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PH; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BACTERIA; COLON; FATTY ACIDS, VOLATILE; FECES; FEMALE; FERMENTATION; FOLLOW-UP STUDIES; HUMANS; HYDROGEN-ION CONCENTRATION; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84969422034     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.220     Document Type: Article

References (49)

1. Drossman DA, Camilleri M, Mayer EA et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31.
2. Spiller R, Aziz Q, Creed F et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98.
3. Barbara G, Cremon C, Carini G et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011;17:349-59.
4. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012;367:1626-35.
5. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303:G775-85.
6. Carroll IM, Ringel-Kulka T, Keku TO et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011;301:G799-G807.
7. Carroll IM, Ringel-Kulka T, Siddle JP et al. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:521-30.e248
8. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011;17:252-66.
9. Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2013;305:G529-41.
10. Chassard C, Dapoigny M, Scott KP et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012;35:828-38.
11. Dapoigny M, Stockbrugger RW, Azpiroz F et al. Role of alimentation in irritable bowel syndrome. Digestion 2003;67:225-33.
12. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187-9.
13. Brenner DM, Moeller MJ, Chey WD et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-49.
14. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
15. Halmos EP, Power VA, Shepherd SJ et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146: 67-75. e5.
16. Staudacher HM, Lomer MC, Anderson JL et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012;142:1510-8.
17. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999;45 Suppl 2:II69-II77.
18. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402.
19. Drossman DA, Patrick DL, Whitehead WE et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999-1007.
20. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-4.
21. Rao SS, Camilleri M, Hasler WL et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol Motil 2011;23:8-23.
22. Rao SS, Kuo B, McCallum RW et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol 2009;7:537-44.
23. Chassard C, Scott KP, Marquet P et al. Assessment of metabolic diversity within the intestinal microbiota from healthy humans using combined molecular and cultural approaches. FEMS Microbiol Ecol 2008;66:496-504
24. Matulova M, Nouaille R, Capek P et al. Degradation of wheat straw by Fibrobacter succinogenes S85: a liquid- and solid-state nuclear magnetic resonance study. Appl Environ Microbiol 2005;71:1247-53.
25. Richardson A, Calder A, Srewart C et al. Simultaneous determination of volatile and non-volatile acidic fermentation products of anaerobes by capillary gas chromatography. Lett Appl Microbiol 1989;9:5-8.
26. Simren M, Barbara G, Flint HJ et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013;62:159-76.
27. Hamer HM, De Preter V, Windey K et al. Functional analysis of colonic bacterial metabolism: relevant to health? Am J Physiol Gastrointest Liver Physiol 2012;302:G1-G9.
28. Wong JM, de Souza R, Kendall CW et al. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006;40:235-43.
29. Eswaran S, Muir J, Chey WD. Fiber and functional gastrointestinal disorders. Am J Gastroenterol 2013;108:718-27.
30. Layden BT, Angueira AR, Brodsky M et al. Short chain fatty acids and their receptors: new metabolic targets. Transl Res 2013;161:131-40.
31. Pimentel M, Soffer EE, Chow EJ et al. Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth. Dig Dis Sci 2002;47:2639-43.
32. Majewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: clinical profiles and effects of antibiotic trial. Adv Med Sci 2007;52:139-42.
33. Majewski M, Reddymasu SC, Sostarich S et al. Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth. Am J Med Sci 2007;333:266-70.
34. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6.
35. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-9.
36. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011;60:334-40.
37. Kamath PS, Hoepfner MT, Phillips SF. Short-chain fatty acids stimulate motility of the canine ileum. Am J Physiol 1987;253:G427-33.
38. Fukumoto S, Tatewaki M, Yamada T et al. Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 2003;284:R1269-76.
39. Winston J, Shenoy M, Medley D et al. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology 2007;132:615-27.
40. Hoverstad T, Bjorneklett A, Fausa O et al. Short-chain fatty acids in the small-bowel bacterial overgrowth syndrome. Scand J Gastroenterol 1985;20:492-9.
41. Tana C, Umesaki Y, Imaoka A et al. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:512-9. e114-5.
42. Treem WR, Ahsan N, Kastoff G et al. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 1996;23:280-6.
43. Roediger WE, Moore A. Effect of short-chaim fatty acid on sodium absorption in isolated human colon perfused through the vascular bed. Dig Dis Sci 1981;26:100-6.
44. Ruppin H, Bar-Meir S, Soergel KH et al. Absorption of short-chain fatty acids by the colon. Gastroenterology 1980;78:1500-7.
45. McNeil NI, Cummings JH, James WP. Short chain fatty acid absorption by the human large intestine. Gut 1978;19:819-22.
46. Camilleri M, Thorne NK, Ringel Y et al. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil 2010;22:874-82. e233.
47. Evans DF, Pye G, Bramley R et al. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988;29:1035-41.
48. Watson BW, Meldrum SJ, Riddle HC et al. pH profile of gut as measured by radiotelemetry capsule. Br Med J 1972;2:104-6.
49. Zarate N, Mohammed SD, O'Shaughnessy E et al. Accurate localization of a fall in pH within the ileocecal region: validation using a dual-scintigraphic technique. Am J Physiol Gastrointest Liver Physiol 2010;299:G1276-86.